Am J Health Syst Pharm. 2007;64(11):1174-1186. In the British study, 495 patients received droperidol 2.5-50 mg p.o. for the treatment of psychiatric illness and were compared with 101 healthy ...

Droperidol was a first-line, highly effective agent for the treatment of PONV for over 30 years. It has the most postmarketing surveillance data of any of the currently used antiemetic agents.